December 2, 2016
Novartis Pharma filed applications in Japan on November 30 for the addition of new aplastic anemia indications for its chronic idiopathic thrombocytopenic purpura treatment Revolade (eltrombopag olamine) and autoimmune disease drug Neoral (ciclosporin). In November, Revolade was designated as an...read more